CASI Pharmaceuticals Inc (CASI)vsJohnson & Johnson (JNJ)
CASI
CASI Pharmaceuticals Inc
$0.21
0.00%
HEALTHCARE · Cap: $4.26M
JNJ
Johnson & Johnson
$283.62
+1.11%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 369918% more annual revenue ($99.33B vs $26.85M). JNJ leads profitability with a 16.2% profit margin vs -184.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
CASI
Avoid24
out of 100
Grade: F
JNJ
Buy54
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1095.0% — below average capital efficiency
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CASI
The strongest argument for CASI centers on Debt/Equity.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : CASI
The primary concerns for CASI are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
CASI profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
CASI carries more volatility with a beta of 0.89 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (54/100 vs 24/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CASI Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · China
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?